Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
North Eastern German Society of Gynaecological Oncology
Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy. None randomised study exists comparing a weekly topotecan application with an application on day 1-5. This study will compare the two applications in regard to: rate of complete or partial remissions, rate of toxicity, quality of life, progression free survival, overall survival.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
patients with histologically-confirmed ovarian cancer